Aprea TherapeuticsAPRE
13F holders, Q2 2024 (June 30)1holders −1
0new positions
1sold out
$3.34avg. 13F price*
At the end of Q2 2024, 1 institutions reported holding Aprea Therapeutics Inc. (APRE) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holder was Lanark Financial, Inc. ($3K).
- Company
- Aprea Therapeutics Inc.
- CUSIP
- 03836J102
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $669 |
All 13F filers, Q1 2024 → Q2 2024: 100 shares sold, net −100 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Lanark Financial, Inc. | 0.00% | No change | 899 | $3K |
"% of holder's portfolio" is APRE's weight in each manager's 13F, not the share of Aprea Therapeutics Inc. the manager owns.